Understanding the prospective of gene therapy for the treatment of breast cancer

IF 0.2 Q4 OBSTETRICS & GYNECOLOGY

Revista de Senologia y Patologia Mamaria Pub Date : 2025-04-03 DOI:10.1016/j.senol.2025.100683

Ritika , Sonam Rani , Rishabha Malviya , Shivam Rajput , Sathvik Belagodu Sridhar , Dinesh Kaushik

{"title":"Understanding the prospective of gene therapy for the treatment of breast cancer","authors":"Ritika , Sonam Rani , Rishabha Malviya , Shivam Rajput , Sathvik Belagodu Sridhar , Dinesh Kaushik","doi":"10.1016/j.senol.2025.100683","DOIUrl":null,"url":null,"abstract":"<div><div>Breast cancer (BC) is the most common type of cancer in women and the second most common cause of death from cancer in women around the world. Local therapies, Systematic therapies and advanced systematic therapies are included in current treatment strategies. Gene therapy has become a hopeful way to treat or stop disease by changing bad genes genetically. This innovative strategy aims to replace defective genes, enhance immune defenses, or silence harmful genes. Recent advances in cancer-specific promoter systems make targeted gene treatments possible. These include using suicide genes, cancer suppressor genes, gene silencing technologies, and gene-editing techniques. Among these, CRISPR and CAR-T therapy have revolutionized genetic editing in cancer research, offering high specificity, precision, cost-effectiveness, and efficiency. This review highlights recent advancements in gene therapy targeting cancer-specific promoters, emphasizing its potential to transform BC treatment.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100683"},"PeriodicalIF":0.2000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de Senologia y Patologia Mamaria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0214158225000192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer (BC) is the most common type of cancer in women and the second most common cause of death from cancer in women around the world. Local therapies, Systematic therapies and advanced systematic therapies are included in current treatment strategies. Gene therapy has become a hopeful way to treat or stop disease by changing bad genes genetically. This innovative strategy aims to replace defective genes, enhance immune defenses, or silence harmful genes. Recent advances in cancer-specific promoter systems make targeted gene treatments possible. These include using suicide genes, cancer suppressor genes, gene silencing technologies, and gene-editing techniques. Among these, CRISPR and CAR-T therapy have revolutionized genetic editing in cancer research, offering high specificity, precision, cost-effectiveness, and efficiency. This review highlights recent advancements in gene therapy targeting cancer-specific promoters, emphasizing its potential to transform BC treatment.

查看原文本刊更多论文

了解基因疗法治疗乳腺癌的前景

乳腺癌（BC）是女性中最常见的癌症类型，也是世界上女性癌症死亡的第二大常见原因。目前的治疗策略包括局部治疗、系统治疗和高级系统治疗。基因疗法已经成为一种有希望通过改变不良基因来治疗或阻止疾病的方法。这种创新的策略旨在取代有缺陷的基因，增强免疫防御，或沉默有害基因。癌症特异性启动子系统的最新进展使靶向基因治疗成为可能。其中包括使用自杀基因、癌症抑制基因、基因沉默技术和基因编辑技术。其中，CRISPR和CAR-T疗法彻底改变了癌症研究中的基因编辑，具有高特异性、高精度、成本效益和效率。本文综述了针对癌症特异性启动子的基因治疗的最新进展，强调了其改变BC治疗的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊